Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase II Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients with Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System

		Keywords:		Dendritic Cell Immunotherapy

		Phase:		Phase 2

		Treatment ID#s:		VT1115 IRB # 3368-07

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: N Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Patients with atypical malignant brain tumor. Tumors may be primary to the CNS or metastatic to the CNS. Metastatic tumors to the brain, such as ovarian and colon, are also eligible, as are recurrent or high risk medulloblastoma/PNETs, ependymomas, anaplastic gliomas, glioblastoma multiforme, meningioma and miscellaneous tumor types.

		Last Updated:		08/18/2007

		Tumor Types:		Anaplastic Astrocytoma Glioblastoma Multiforme Medulloblastoma Meningioma Metastatic Brain Tumor PNET Tumor


		Comments:		This study is being done to determine whether vaccinations with the subject`s own immune cells called dendritic cells (after they are mixed with proteins from the subject?s brain tumor cells) can activate the subject`s immune system to fight their brain tumor. Tumor cells are taken at the time of surgery and are frozen and thawed to separate protein segments that are unique to that tumor. These proteins will be added to another culture of the subject`s dendritic cells grown from their blood, combined together, then re-injected back into the subject`s body. Dendritic cells are a small group of cells contained in everyone`s white blood cell population. These cells are responsible for letting the immune system know that something foreign, like bacteria, or a tumor, is in the body. Dendritic cells help the body ward off disease by alerting the immune system. The purpose of this study is to evaluate and test the safety of subcutaneous (beneath the skin) injections of the subject`s own dendritic cells that have been removed from the subject`s peripheral blood and cultured with tumor protein fragments from the subject`s brain tumor.

		Treatment Type:		Immunological, Biological or Targeted Therapy.

		Contact:		Cedars-Sinai Maxine Dunitz Neurosurgical Institute Keith L. Black, MD Director 8631 W. Third Street Suite 800 E Los Angeles, CA 90048 Phone:310-423-7900 Fax: (310) 423-0810 Click here to send an email Website: www.cedars-sinai.edu/mdnsi

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By